{"id":"NCT00191386","sponsor":"Eli Lilly and Company","briefTitle":"Long-Term Study of Atomoxetine in Children With Attention-Deficit/Hyperactivity Disorder (AD/HD)","officialTitle":"Long-Term Extension, Open-Label Study of Atomoxetine Hydrochloride in Child Outpatients With Attention-Deficit/Hyperactivity Disorder","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-05","primaryCompletion":"2009-08","completion":"2009-08","firstPosted":"2005-09-19","resultsPosted":"2010-11-10","lastUpdate":"2010-12-28"},"enrollment":228,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Attention Deficit Hyperactivity Disorder"],"interventions":[{"type":"DRUG","name":"Atomoxetine hydrochloride","otherNames":["LY139603","Strattera"]}],"arms":[{"label":"Atomoxetine","type":"EXPERIMENTAL"}],"summary":"The study is long-term extension study to evaluate long-term safety and efficacy of Atomoxetine in Japanese pediatric patients with Attention-Deficit/Hyperactivity Disorder (AD/HD).","primaryOutcome":{"measure":"Number of Participants With Adverse Events for Long Term Safety and Tolerability","timeFrame":"Baseline through 4 years","effectByArm":[{"arm":"Atomoxetine","deltaMin":6,"sd":null}],"pValues":[]},"eligibility":{"minAge":"6 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":1},"locations":{"siteCount":24,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":228},"commonTop":["Nasopharyngitis","Headache","Influenza","Abdominal pain","Upper respiratory tract inflammation"]}}